Targeted disease-specific therapy for patients with hereditary transthyretin amyloidosis and cardiac involvement after orthotopic liver transplantation. Consensus from the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology and National Reference Centers for Familial Amyloidosis
Sílvia Aguiar Rosa(Administração Regional de Saúde de Lisboa e Vale do Tejo), Olga Azevedo(British Heart Foundation), Isabel Conceição(Université Paris-Sud), Teresa Coelho(Administração Regional de Saúde de Lisboa e Vale do Tejo), Catarina Ferreira(University of Trás-os-Montes and Alto Douro), Nuno Marques(Hospital do Espírito Santo)
Cited by 0
Related Papers
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|410
Assessing cognitive decline in the aging brain: lessons from rodent and human studies
|npj Aging|2023|170
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
|The Lancet Neurology|2020|160
Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis
|Journal of the American College of Cardiology|2020|104